ES2638971T3 - Métodos para predecir y monitorizar la cicatrización de la mucosa - Google Patents
Métodos para predecir y monitorizar la cicatrización de la mucosa Download PDFInfo
- Publication number
- ES2638971T3 ES2638971T3 ES13779638.9T ES13779638T ES2638971T3 ES 2638971 T3 ES2638971 T3 ES 2638971T3 ES 13779638 T ES13779638 T ES 13779638T ES 2638971 T3 ES2638971 T3 ES 2638971T3
- Authority
- ES
- Spain
- Prior art keywords
- asca
- tnfa
- areg
- hgf
- fgf1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 86
- 230000035876 healing Effects 0.000 title claims abstract description 85
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims abstract description 452
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 452
- 102100020873 Interleukin-2 Human genes 0.000 claims abstract description 452
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims abstract description 451
- 108090001007 Interleukin-8 Proteins 0.000 claims abstract description 445
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 444
- 108700028353 OmpC Proteins 0.000 claims abstract description 306
- 239000003550 marker Substances 0.000 claims abstract description 146
- -1 HRGB Proteins 0.000 claims abstract description 74
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 72
- 230000035755 proliferation Effects 0.000 claims abstract description 54
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 45
- 239000003814 drug Substances 0.000 claims abstract description 27
- 229940079593 drug Drugs 0.000 claims abstract description 27
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims abstract description 20
- 101800001382 Betacellulin Proteins 0.000 claims abstract description 15
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims abstract description 15
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 claims abstract description 15
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 claims abstract description 15
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 claims abstract description 15
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 claims abstract description 15
- 101000611888 Homo sapiens Platelet-derived growth factor C Proteins 0.000 claims abstract description 15
- 101000655540 Homo sapiens Protransforming growth factor alpha Proteins 0.000 claims abstract description 15
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims abstract description 15
- 101000742579 Homo sapiens Vascular endothelial growth factor B Proteins 0.000 claims abstract description 15
- 101000742596 Homo sapiens Vascular endothelial growth factor C Proteins 0.000 claims abstract description 15
- 101000742599 Homo sapiens Vascular endothelial growth factor D Proteins 0.000 claims abstract description 15
- 102000003814 Interleukin-10 Human genes 0.000 claims abstract description 15
- 108090000174 Interleukin-10 Proteins 0.000 claims abstract description 15
- 102100040681 Platelet-derived growth factor C Human genes 0.000 claims abstract description 15
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 claims abstract description 15
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 claims abstract description 15
- 102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 claims abstract description 15
- 108010019674 Proto-Oncogene Proteins c-sis Proteins 0.000 claims abstract description 15
- 102100032350 Protransforming growth factor alpha Human genes 0.000 claims abstract description 15
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims abstract description 15
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 claims abstract description 15
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims abstract description 15
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims abstract description 15
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims abstract description 15
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 claims abstract description 14
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 claims abstract description 14
- 101100227197 Arabidopsis thaliana FLA2 gene Proteins 0.000 claims abstract 3
- 241000208202 Linaceae Species 0.000 claims abstract 3
- 235000004431 Linum usitatissimum Nutrition 0.000 claims abstract 3
- 102100038778 Amphiregulin Human genes 0.000 claims abstract 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims abstract 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims abstract 2
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 claims abstract 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims abstract 2
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims abstract 2
- 101000809450 Homo sapiens Amphiregulin Proteins 0.000 claims abstract 2
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 claims abstract 2
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 claims abstract 2
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 claims abstract 2
- 101001027380 Homo sapiens Fibroblast growth factor 9 Proteins 0.000 claims abstract 2
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims abstract 2
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 claims abstract 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims abstract 2
- 101001056707 Homo sapiens Proepiregulin Proteins 0.000 claims abstract 2
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims abstract 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims abstract 2
- 102100020880 Kit ligand Human genes 0.000 claims abstract 2
- 101710177504 Kit ligand Proteins 0.000 claims abstract 2
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims abstract 2
- 102100029837 Probetacellulin Human genes 0.000 claims abstract 2
- 102100025498 Proepiregulin Human genes 0.000 claims abstract 2
- 230000037390 scarring Effects 0.000 claims description 47
- 238000004422 calculation algorithm Methods 0.000 claims description 43
- 108010008165 Etanercept Proteins 0.000 claims description 31
- 229960000598 infliximab Drugs 0.000 claims description 25
- 210000004877 mucosa Anatomy 0.000 claims description 25
- 239000000090 biomarker Substances 0.000 claims description 23
- 208000011231 Crohn disease Diseases 0.000 claims description 19
- 229960002964 adalimumab Drugs 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 18
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 16
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 16
- 229960003115 certolizumab pegol Drugs 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 16
- 229960000403 etanercept Drugs 0.000 claims description 16
- 229940073621 enbrel Drugs 0.000 claims description 15
- 229940048921 humira Drugs 0.000 claims description 15
- 229940116176 remicade Drugs 0.000 claims description 15
- 210000001519 tissue Anatomy 0.000 claims description 15
- 210000004027 cell Anatomy 0.000 claims description 14
- 229940090100 cimzia Drugs 0.000 claims description 14
- 238000002560 therapeutic procedure Methods 0.000 claims description 12
- 238000012544 monitoring process Methods 0.000 claims description 11
- 238000001356 surgical procedure Methods 0.000 claims description 11
- 238000001574 biopsy Methods 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 210000002381 plasma Anatomy 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 10
- 230000000391 smoking effect Effects 0.000 claims description 9
- 238000011285 therapeutic regimen Methods 0.000 claims description 9
- 238000003745 diagnosis Methods 0.000 claims description 8
- 230000002250 progressing effect Effects 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 6
- 238000009175 antibody therapy Methods 0.000 claims description 5
- 210000003608 fece Anatomy 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 230000000405 serological effect Effects 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 474
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 463
- 108010074051 C-Reactive Protein Proteins 0.000 description 459
- 102100032752 C-reactive protein Human genes 0.000 description 459
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 457
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 457
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 452
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 451
- 102000004890 Interleukin-8 Human genes 0.000 description 443
- 102000004889 Interleukin-6 Human genes 0.000 description 442
- 239000012071 phase Substances 0.000 description 123
- 241000282414 Homo sapiens Species 0.000 description 30
- 239000000523 sample Substances 0.000 description 22
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 17
- 230000008439 repair process Effects 0.000 description 16
- 102400001242 Betacellulin Human genes 0.000 description 13
- 101800003838 Epidermal growth factor Proteins 0.000 description 13
- 102400001368 Epidermal growth factor Human genes 0.000 description 13
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 13
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 13
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 13
- 101710153349 Fibroblast growth factor 19 Proteins 0.000 description 13
- 108090000367 Fibroblast growth factor 9 Proteins 0.000 description 13
- 229940116977 epidermal growth factor Drugs 0.000 description 13
- 229940126864 fibroblast growth factor Drugs 0.000 description 13
- 229940029303 fibroblast growth factor-1 Drugs 0.000 description 13
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 11
- 230000003110 anti-inflammatory effect Effects 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 238000007634 remodeling Methods 0.000 description 11
- 108091058560 IL8 Proteins 0.000 description 10
- 102100040247 Tumor necrosis factor Human genes 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 241000237536 Mytilus edulis Species 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 235000020638 mussel Nutrition 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 229940076144 interleukin-10 Drugs 0.000 description 7
- 210000004347 intestinal mucosa Anatomy 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 6
- 102100039065 Interleukin-1 beta Human genes 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000006073 displacement reaction Methods 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000036269 ulceration Effects 0.000 description 3
- 241000282465 Canis Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- HDBQZGJWHMCXIL-UHFFFAOYSA-N 3,7-dihydropurine-2-thione Chemical compound SC1=NC=C2NC=NC2=N1 HDBQZGJWHMCXIL-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100099867 Bos taurus TNF gene Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010067671 Disease complication Diseases 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010022714 Intestinal ulcer Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 101100046535 Rattus norvegicus Tnf gene Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000144290 Sigmodon hispidus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000011622 Testicular disease Diseases 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229960003950 combination of corticosteroids Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000009442 healing mechanism Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007737 ion beam deposition Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000000492 lymphangiogenic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000019 nipple aspirate fluid Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000010388 wound contraction Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261710491P | 2012-10-05 | 2012-10-05 | |
| US201261710491P | 2012-10-05 | ||
| US201361824959P | 2013-05-17 | 2013-05-17 | |
| US201361824959P | 2013-05-17 | ||
| PCT/IB2013/059077 WO2014054013A1 (en) | 2012-10-05 | 2013-10-02 | Methods for predicting and monitoring mucosal healing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2638971T3 true ES2638971T3 (es) | 2017-10-24 |
Family
ID=49447587
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13779638.9T Active ES2638971T3 (es) | 2012-10-05 | 2013-10-02 | Métodos para predecir y monitorizar la cicatrización de la mucosa |
| ES17167637T Active ES2771127T3 (es) | 2012-10-05 | 2013-10-02 | Métodos para predecir y monitorizar la cicatrización de la mucosa |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17167637T Active ES2771127T3 (es) | 2012-10-05 | 2013-10-02 | Métodos para predecir y monitorizar la cicatrización de la mucosa |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150355195A1 (cg-RX-API-DMAC10.html) |
| EP (3) | EP3640645A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2015532425A (cg-RX-API-DMAC10.html) |
| CN (1) | CN104838270A (cg-RX-API-DMAC10.html) |
| AU (2) | AU2013326070A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2887035A1 (cg-RX-API-DMAC10.html) |
| ES (2) | ES2638971T3 (cg-RX-API-DMAC10.html) |
| HK (1) | HK1213051A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX358730B (cg-RX-API-DMAC10.html) |
| SG (1) | SG11201502646RA (cg-RX-API-DMAC10.html) |
| WO (1) | WO2014054013A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3295783A1 (en) | 2011-05-10 | 2026-03-02 | Prometheus Laboratories, Inc. | Methods of disease activity profiling for personalized therapy management |
| WO2016063223A1 (en) * | 2014-10-20 | 2016-04-28 | Nestec S.A. | Methods for predicting clinical outcomes in subjects afflicted with ulcerative colitis |
| US20170258820A1 (en) | 2014-10-29 | 2017-09-14 | Glycom A/S | Synthetic composition and method for promoting mucosal healing |
| GB201501612D0 (en) * | 2015-01-30 | 2015-03-18 | Univ Birmingham | Assay |
| CN109462996A (zh) | 2016-03-17 | 2019-03-12 | 西达-赛奈医疗中心 | 通过rnaset2诊断炎性肠病的方法 |
| GB201611738D0 (en) * | 2016-07-05 | 2016-08-17 | Cambridge Entpr Ltd | Biomarkers for inflammatory bowel disease |
| KR20200009095A (ko) * | 2017-05-31 | 2020-01-29 | 프로메테우스 바이오사이언시즈, 인크. | 크론병 환자에서 점막 치유를 평가하는 방법 |
| WO2020112890A1 (en) | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Rnaset2 compositions and methods of treatment therewith |
| CN110646620A (zh) * | 2019-09-29 | 2020-01-03 | 湖北新纵科病毒疾病工程技术有限公司 | 一种同时检测四项炎症标志物的方法及其试剂盒 |
| CN111477325A (zh) * | 2020-04-09 | 2020-07-31 | 赣南师范大学 | 基于粒子群优化算法对引发肠道溃疡疾病进行鉴别的方法 |
| CN120600283B (zh) * | 2025-05-29 | 2026-02-17 | 北京大学第三医院（北京大学第三临床医学院） | 一种基于临床知识图谱的中医生殖内分泌疾病诊断辅助系统 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830675A (en) | 1993-03-10 | 1998-11-03 | Cedars-Sinai Medical Center | Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis |
| EP0615129B1 (en) | 1993-03-10 | 2000-05-31 | Cedars-Sinai Medical Center | Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis or primary sclerosing cholangitis |
| US6218129B1 (en) | 1998-05-15 | 2001-04-17 | Prometheus Laboratories, Inc. | Inflammatory bowel disease first step assay system |
| US6406862B1 (en) | 1998-10-06 | 2002-06-18 | The United States Of America As Represented By The Secretary Of The Army | Dip-stick assay for C-reactive protein |
| FR2802536B1 (fr) | 1999-11-23 | 2003-06-13 | Chru Lille | Oligomannosides de synthese, leur preparation et leur utilisation a la detection d'anticorps et a la prevention d'infections |
| US6838250B2 (en) | 2000-03-31 | 2005-01-04 | Ortho-Clinical Diagnostics, Inc. | Immunoassay for C-reactive protein |
| AU2001253746A1 (en) * | 2000-04-20 | 2001-11-07 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Inducible plasmid vector encoding tgf-beta and uses thereof |
| US7138237B1 (en) | 2000-05-19 | 2006-11-21 | Cedars-Sinai Medical Center | Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen |
| EP1581119B1 (en) | 2001-12-17 | 2013-01-30 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
| US20040197304A1 (en) * | 2003-04-01 | 2004-10-07 | The Procter & Gamble Company And Alimentary Health, Ltd. | Methods of determining efficacy of treatments of inflammatory diseases of the bowel |
| CA2549971A1 (en) | 2003-11-03 | 2005-05-12 | Duke University | Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke |
| WO2006012472A1 (en) | 2004-07-21 | 2006-02-02 | Qualyst, Inc. | Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation |
| WO2007087576A2 (en) | 2006-01-24 | 2007-08-02 | The Uab Research Foundation | Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases |
| CN104198705B (zh) | 2006-09-21 | 2017-06-09 | 雀巢产品技术援助有限公司 | 检测稀有循环细胞内多种信号转导分子的基于抗体的阵列 |
| NZ582618A (en) | 2007-07-13 | 2012-07-27 | Prometheus Lab Inc | Drug selection for lung cancer therapy using antibody-based arrays |
| ES2553390T3 (es) | 2008-02-25 | 2015-12-09 | Nestec S.A. | Método para la detección de receptores truncados intracelulares |
| CN101780269A (zh) * | 2009-01-21 | 2010-07-21 | 北京三有利科技发展有限公司 | 细胞生长因子治疗溃疡性疾病和肺纤维化疾病的应用 |
| NZ596468A (en) | 2009-05-14 | 2013-11-29 | Nestec Sa | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
| JP5795311B2 (ja) | 2009-07-15 | 2015-10-14 | ネステク ソシエテ アノニム | 抗体ベースのアレイを使用する胃癌療法のための薬物選択 |
| DK2491385T3 (en) | 2009-10-20 | 2017-08-28 | Diatech Holdings Inc | PROXIMITY-MEDIED ASSAYS FOR DETECTING ONCOGEN FUSION PROTEINS |
| CN104634955B (zh) | 2009-10-26 | 2016-09-14 | 雀巢产品技术援助有限公司 | 检测抗-tnf药物和自身抗体的试验 |
| CA2781654A1 (en) * | 2009-11-25 | 2011-06-03 | Hua Gong | Novel genomic biomarkers for irritable bowel syndrome diagnosis |
| EP2576838A4 (en) * | 2010-06-04 | 2019-05-15 | Nestec S.A. | METHOD FOR IMPROVING DIAGNOSIS OF INFLAMMATORY ENDURANCE |
| WO2012054532A1 (en) | 2010-10-18 | 2012-04-26 | Prometheus Laboratories Inc. | Methods for determining anti-drug antibody isotypes |
| SG191230A1 (en) | 2010-12-23 | 2013-07-31 | Nestec Sa | Drug selection for malignant cancer therapy using antibody-based arrays |
| MX343327B (es) | 2011-02-17 | 2016-11-01 | Nestec Sa | Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa. |
| EP2681552A2 (en) | 2011-03-02 | 2014-01-08 | Nestec S.A. | Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures |
| WO2013006810A1 (en) | 2011-07-06 | 2013-01-10 | Nestec Sa | Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha |
| KR101851425B1 (ko) | 2011-09-02 | 2018-04-23 | 네스텍 소시에테아노님 | 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링 |
-
2013
- 2013-10-02 ES ES13779638.9T patent/ES2638971T3/es active Active
- 2013-10-02 CA CA2887035A patent/CA2887035A1/en not_active Abandoned
- 2013-10-02 EP EP19212960.9A patent/EP3640645A1/en not_active Withdrawn
- 2013-10-02 JP JP2015535153A patent/JP2015532425A/ja active Pending
- 2013-10-02 SG SG11201502646RA patent/SG11201502646RA/en unknown
- 2013-10-02 EP EP17167637.2A patent/EP3217179B9/en active Active
- 2013-10-02 HK HK16100852.9A patent/HK1213051A1/zh unknown
- 2013-10-02 AU AU2013326070A patent/AU2013326070A1/en not_active Abandoned
- 2013-10-02 MX MX2015004272A patent/MX358730B/es active IP Right Grant
- 2013-10-02 EP EP13779638.9A patent/EP2904405B1/en not_active Not-in-force
- 2013-10-02 ES ES17167637T patent/ES2771127T3/es active Active
- 2013-10-02 WO PCT/IB2013/059077 patent/WO2014054013A1/en not_active Ceased
- 2013-10-02 CN CN201380063566.2A patent/CN104838270A/zh active Pending
-
2015
- 2015-04-03 US US14/678,455 patent/US20150355195A1/en not_active Abandoned
-
2019
- 2019-06-19 AU AU2019204276A patent/AU2019204276A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019204276A1 (en) | 2019-07-04 |
| CA2887035A1 (en) | 2014-04-10 |
| ES2771127T3 (es) | 2020-07-06 |
| MX2015004272A (es) | 2015-08-14 |
| CN104838270A (zh) | 2015-08-12 |
| AU2013326070A1 (en) | 2015-04-23 |
| EP3217179A1 (en) | 2017-09-13 |
| SG11201502646RA (en) | 2015-05-28 |
| EP3217179B1 (en) | 2020-01-08 |
| EP2904405B1 (en) | 2017-05-31 |
| EP3217179B9 (en) | 2020-06-10 |
| EP3640645A1 (en) | 2020-04-22 |
| MX358730B (es) | 2018-09-03 |
| WO2014054013A1 (en) | 2014-04-10 |
| US20150355195A1 (en) | 2015-12-10 |
| EP2904405A1 (en) | 2015-08-12 |
| JP2015532425A (ja) | 2015-11-09 |
| HK1213051A1 (zh) | 2016-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2771127T3 (es) | Métodos para predecir y monitorizar la cicatrización de la mucosa | |
| US12485171B2 (en) | Methods of disease activity profiling for personalized therapy management | |
| ES2536088T3 (es) | Métodos para el diagnóstico del síndrome de intestino irritable | |
| CN103299190B (zh) | 确定抗药物抗体同种型的方法 | |
| US10697961B2 (en) | Methods for predicting post-operative recurrence of Crohn's disease | |
| WO2015110989A1 (en) | Biomarker panel for assessment of mucosal healing | |
| HK40017436A (en) | Methods of disease activity profiling for personalized therapy management | |
| NZ617009B2 (en) | Methods of disease activity profiling for personalized therapy management | |
| NZ711144B2 (en) | Methods of disease activity profiling for personalized therapy management |